Recerca

Àrea 4

Malalties neurodegeneratives: Investigació clínica i experimental

Factor d'impacte: mitjana: 5.15, total: 273.09

Articles de l'any 2011
Original
  • Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy

    Guevara M, Baccaro ME, Gomez-Anson B, Frisoni G, Testa C, Torre A, Molinuevo JL, Rami L, Pereira G, Sotil EU, Cordoba J, Arroyo V, Gines P
    J HEPATOL. 2011; 55: 564-573. IF: 9.334

  • Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid beta-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas

    Fortea J, Sala-Llonch R, Bartres-Faz D, Llado A, Sole-Padulles C, Bosch B, Antonell A, Olives J, Sanchez-Valle R, Molinuevo JL, Rami L
    BIOL PSYCHIAT. 2011; 70: 183-190. IF: 8.674

  • Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease

    Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A
    NEUROLOGY. 2011; 76: 1720-1725. IF: 8.017

  • Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study)

    Moreno-Lopez C, Santamaria J, Salamero M, DelSorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser T, Tolosa E
    ARCH NEUROL-CHICAGO. 2011; 68: 223-230. IF: 7.108

  • Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration

    Chen-Plotkin AS, Martinez-Lage M, Sleiman PMA, Hu W, Greene R, Wood EM, Bing SX, Grossman M, Schellenberg GD, Hatanpaa KJ, Weiner MF, White CL, Brooks WS, Halliday GM, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, VanSwieten JC, Heutink P, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Bigio E, Llado A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IRA, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, DeDeyn PP, VanBroeckhoven C, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, Lee VMY, Trojanowski JQ, VanDeerlin VM
    ARCH NEUROL-CHICAGO. 2011; 68: 488-497. IF: 7.108

  • Dysfunctions of cerebral networks precede recognition memory deficits in early Parkinson's disease

    Ibarretxe-Bilbao N, Zarei M, Junque C, Marti MJ, Segura B, Vendrell P, Valldeoriola F, Bargallo N, Tolosa E
    NEUROIMAGE. 2011; 57: 589-597. IF: 5.937

  • The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

    Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, Mcauliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, DeReus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, VanBroeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K
    ALZHEIMERS DEMENT. 2011; 7: 386-395. IF: 5.902

  • Diagnostic cutoff points for I-123-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease

    Muxi A, Paredes P, Navales I, Valldeoriola F, Gaig C, Lomena F, DeLaCerda A, Sola O, Domenech B, Tolosa E, Pons F
    EUR J NUCL MED MOL I. 2011; 38: 1139-1146. IF: 5.036

  • Mitochondrial Injury in Human Acute Carbon Monoxide Poisoning: The Effect of Oxygen Treatment

    Garrabou G, Inoriza JM, Moren C, Oliu G, Miro O, Marti MJ, Cardellach F
    J ENVIRON SCI HEAL C. 2011; 29: 32-51. IF: 4.84

  • Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER)

    Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR
    MOVEMENT DISORD. 2011; 26: 90-99. IF: 4.48

  • Rapidly Progressive Diffuse Lewy Body Disease

    Gaig C, Valldeoriola F, Gelpi E, Ezquerra M, Llufriu S, Buongiorno M, Rey MJ, Marti MJ, Graus F, Tolosa E
    MOVEMENT DISORD. 2011; 26: 1316-1323. IF: 4.48

  • Replication of top markers of a genome-wide association study in multiple sclerosis in Spain

    Cavanillas ML, Fernandez O, Comabella M, Alcina A, Fedetz M, Izquierdo G, Lucas M, Cenit MC, Arroyo R, Vandenbroeck K, Alloza I, Garcia-Barcina M, Antiguedad A, Leyva L, Gomez CL, Olascoaga J, Otaegui D, Blanco Y, Saiz A, Montalban X, Matesanz F, Urcelay E
    GENES IMMUN. 2011; 12: 110-115. IF: 4.367

  • Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients

    Rami L, Fortea J, Bosch B, Sole-Padulles C, Llado A, Iranzo A, Sanchez-Valle R, Molinuevo JL
    J ALZHEIMERS DIS. 2011; 23: 1-8. IF: 4.261

  • Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

    Hoglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang LS, Klei L, Rademakers R, DeSilva R, Litvan I, Riley DE, VanSwieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, VanDerBrug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD
    NAT GENET. 2011; 43: 699-0. IF: 36.377

  • A tool to improve pre-selection for deep brain stimulation in patients with Parkinson's disease

    Wachter T, Minguez-Castellanos A, Valldeoriola F, Herzog J, Stoevelaar H
    J NEUROL. 2011; 258: 641-646. IF: 3.853

  • Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C)

    Munoz E, Iranzo A, Rauek S, Lomena F, Gallego J, Ros D, Santamaria J, Tolosa E
    J NEUROL. 2011; 258: 2248-2253. IF: 3.853

  • I-123-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations

    Valldeoriola F, Gaig C, Muxi A, Navales I, Paredes P, Lomena F, DeLaCerda A, Buongiorno M, Ezquerra M, Santacruz P, Marti MJ, Tolosa E
    J NEUROL. 2011; 258: 1126-1132. IF: 3.853

  • Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with PSEN1 Mutations

    Fortea J, Llado A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sanchez-Valle R
    NEURODEGENER DIS. 2011; 8: 202-207. IF: 3.791

  • Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease

    Botta-Orfila T, Ezquerra M, Rios J, Fernandez-Santiago R, Cervantes S, Samaranch L, Pastor P, Marti MJ, Munoz E, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E
    EUR J NEUROL. 2011; 18: 0-0. IF: 3.765

  • Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study

    Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Camara A, Gaig C, Compta Y
    EUR J NEUROL. 2011; 18: 980-987. IF: 3.765

  • In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression

    Marin C, Aguilar E
    NEUROCHEM INT. 2011; 58: 521-526. IF: 3.601

  • Specific Anatomic Associations Between White Matter Integrity and Cognitive Reserve in Normal and Cognitively Impaired Elders

    Arenaza-Urquijo EM, Bosch B, Sala-Llonch R, Sole-Padulles C, Junque C, Fernandez-Espejo D, Bargallo N, Rami L, Molinuevo JL, Bartres-Faz D
    AM J GERIAT PSYCHIAT. 2011; 19: 33-42. IF: 3.566

  • Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder

    Iranzo A, Frauscher B, Santos H, Gschliesser V, Ratti L, Falkenstetter T, Sturner C, Salamero M, Tolosa E, Poewe W, Santamaria J, Hogl B
    SLEEP MED. 2011; 12: 284-288. IF: 3.43

  • Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study

    Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, Pavia J, Santamaria J, Tolosa E
    LANCET NEUROL. 2011; 10: 797-805. IF: 21.659

  • A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

    Rascol O, Fitzer-Attas C, Hauser R, Jankovic J, Long A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW
    LANCET NEUROL. 2011; 10: 415-423. IF: 21.659

  • The Metabotropic Glutamate Receptor Antagonist 2-Methyl-6-(phenylethynyl) pyridine Decreases Striatal VGLUT2 Expression in Association With an Attenuation of L-Dopa-Induced Dyskinesias

    Marin C, Bonastre M, Aguilar E, Jimenez A
    SYNAPSE. 2011; 65: 1080-1086. IF: 2.925

  • Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints

    Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez-Valle R, Iranzo A, Molinuevo JL, Llado A
    J NEURAL TRANSM. 2011; 118: 259-262. IF: 2.597

  • Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test

    Quintana M, Pena-Casanova J, Sanchez-Benavides G, Langohr K, Manero RM, Aguilar M, Badenes D, Molinuevo JL, Robles A, Barquero MS, Antunez C, Martinez-Parra C, Frank-Garcia A, Fernandez M, Blesa R
    ARCH CLIN NEUROPSYCH. 2011; 26: 144-157. IF: 2.304

  • Modulation of the soleus H reflex by electrical subcortical stimuli in humans

    Costa J, Guzman J, Valldeoriola F, Rumia J, Tolosa E, Casanova-Molla J, Valls-Sole J
    EXP BRAIN RES. 2011; 212: 439-448. IF: 2.296

  • Progress in defining the premotor phase of Parkinson's disease

    Tolosa E, Pont-Sunyer C
    J NEUROL SCI. 2011; 310: 4-8. IF: 2.167

  • Amyloid-beta and tau biomarkers in Parkinson's disease-dementia

    Buongiorno M, Compta Y, Marti MJ
    J NEUROL SCI. 2011; 310: 25-30. IF: 2.167

  • Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease

    Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E
    J NEUROL SCI. 2011; 310: 70-74. IF: 2.167

  • Cerebral basis of visual hallucinations in Parkinson's disease: Structural and functional MRI studies

    Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E
    J NEUROL SCI. 2011; 310: 79-81. IF: 2.167

  • Alpha- and beta-synuclein expression in Parkinson disease with and without dementia

    Beyer K, Ispierto L, Latorre P, Tolosa E, Ariza A
    J NEUROL SCI. 2011; 310: 112-117. IF: 2.167

  • Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum

    Sole-Padulles C, Llado A, Bartres-Faz D, Fortea J, Sanchez-Valle R, Bosch B, Antonell A, Molinuevo JL, Rami L
    PSYCHIAT RES-NEUROIM. 2011; 192: 140-146. IF: 2.064

  • High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease

    Compta Y, Ezquerra M, Munoz E, Tolosa E, Valldeoriola F, Rios J, Camara A, Fernandez M, Buongiorno MT, Marti MJ
    NEUROSCI LETT. 2011; 487: 169-173. IF: 2.055

  • A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease

    Antonell A, Balasa M, Oliva R, Llado A, Bosch B, Fabregat N, Fortea J, Molinuevo JL, Sanchez-Valle R
    NEUROSCI LETT. 2011; 496: 40-42. IF: 2.055

  • White and Gray Matter Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Diffusion-Tensor Imaging and Voxel-Based Morphometry Study

    Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, Santamaria J, Tolosa E, Hogl B, Poewe W
    ANN NEUROL. 2011; 69: 400-407. IF: 10.746

  • Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: Implications for early diagnosis and treatment

    Molinuevo JL, Berthier ML, Rami L
    ARCH GERONTOL GERIAT. 2011; 52: 18-22. IF: 1.438

  • Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates

    Molinuevo JL, Gomez-Anson B, Monte GC, Bosch B, Sanchez-Valle R, Rami L
    ARCH GERONTOL GERIAT. 2011; 52: 190-196. IF: 1.438

  • Cognitive reserve questionnaire. Scores obtained in a healthy elderly population and in one with Alzheimer's disease

    Rami L, Valls-Pedret C, Bartres-Faz D, Caprile C, Sole-Padulles C, Castellvi M, Olives J, Bosch B, Molinuevo JL
    REV NEUROLOGIA. 2011; 52: 195-201. IF: 1.218

  • Landscape test for assessing visual memory in Alzheimer's disease

    Valls-Pedret C, Olives J, Bosch B, Caprile C, Castellvi M, Molinuevo JL, Rami L
    REV NEUROLOGIA. 2011; 53: 1-7. IF: 1.218

  • PICOGEN: Five years experience with a genetic counselling program for dementia

    Fortea J, Llado A, Clarimon J, Lleo A, Oliva R, Peri J, Pintor L, Yague J, Blesa R, Molinuevo JL, Sanchez-Valle R
    NEUROLOGIA. 2011; 26: 143-149. IF: 0.589

  • Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease

    Molinuevo JL, Hernandez B
    NEUROLOGIA. 2011; 26: 518-527. IF: 0.589

Revisió
  • Monoclonal antibody therapy-associated neurological disorders

    Bosch X, Saiz A, Ramos-Casals M
    NAT REV NEUROL. 2011; 7: 165-172. IF: 6.511

  • Milestones in Atypical and Secondary Parkinsonisms

    Wenning GK, Litvan I, Tolosa E
    MOVEMENT DISORD. 2011; 26: 1083-1095. IF: 4.48

  • Memantine: the value of combined therapy

    Molinuevo JL
    REV NEUROLOGIA. 2011; 52: 95-100. IF: 1.218

Multicèntrics
  • Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study

    Frolich L, Ashwood T, Nilsson J, Eckerwall G
    J ALZHEIMERS DIS. 2011; 24: 363-374. IF: 4.261

Tornar